Page 3 - Temporary Authorization News Today : Breaking News, Live Updates & Top Stories | Vimarsana

PTC Therapeutics Announces Commercial Milestone Payment Following the Recent European Approval of Evrysdi™ News provided by Share this article Share this article SOUTH PLAINFIELD, N.J., April 1, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that a $20 million milestone payment was triggered by the first commercial sale of Evrysdi™ (risdiplam) in the European Union under its License and Collaboration Agreement with Roche. Approval for Evrysdi from the European Medicines Agency was received on March 30 for the treatment of spinal muscular atrophy (SMA) in adult...

Early Access to BioCryst’s Berotralstat Granted for HAE Patients in France News Provided By Share This Article For investors and media only RESEARCH TRIANGLE PARK, N.C., March 11, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the French National Agency for Medicines and Health Products Safety (ANSM) has granted an Autorisation Temporaire d'Utilisation de cohorte (cohort ATU), or Temporary Authorization for Use, for the use of berotralstat to prevent attacks of hereditary angioedema (HAE) in appropriate patients aged 12 and older. This cohort A...

Press release content from Business Wire. The AP news staff was not involved in its creation. Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Period Activity February 11, 2021 GMT CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 11, 2021-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year ended December 31, 2020 and reviewed recent business highlights. “We’re very pleased with the 2020 commercial performance for our marke...

ABIONYX Pharma: ABIONYX Initiates a Phase 2a Clinical Trial With CER-001 in Septic Patients at High Risk of Developing Acute Kidney Injury Temporary Authorization for Named Use (ATUn) showed promising efficacy in renal diseases Evaluation of the clinical activity by dosage level of CER-001 in the prevention of Acute Kidney Injury in ICU patients with septicemia A potentially modifying effect on the progression of the inflammatory cascade in sepsis Pending positive data, the company aims to move into Phase 2b by end of 2021 Regulatory News: ABIONYX Pharma ( FR0012616852 ABNX PEA PME eligible),...